<DOC>
	<DOCNO>NCT02819856</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability SPI-1005 treatment CF patient active pulmonary exacerbation receive IV course tobramycin , use history , physical exam , vital sign ( VS ) , adverse event ( AE ) reporting , hematology ( CBC ) chemistry ( Chem-20 ) . The secondary objective study determine pharmacokinetics oral SPI-1005 200 , 400 600 mg BID 14 day . Peak/trough assessment determine ebselen , major metabolite selenium . Clinical assessment severity sensorineural hearing loss , speech discrimination , vertigo severity , tinnitus severity lung function make compare treatment arm placebo arm study .</brief_summary>
	<brief_title>SPI-1005 Prevention Treatment Aminoglycoside Induced Ototoxicity</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , dose-escalating , safety , PK , PD study oral SPI-1005 CF patient active pulmonary exacerbation receive 14-day course IV tobramycin ( 10 mg/kg/d ) . All patient undergo baseline test severity lung function , sensorineural hearing loss , tinnitus vertigo determine start SPI-1005 treatment . SPI-1005 treatment start within first two day IV tobramycin treatment administer concomitantly . At end 14-day course SPI-1005 28 day follow cessation SPI-1005 , patient hear loss , tinnitus vertigo reassess . Assessments may also include additional audiometric pulmonary testing , additional follow-up testing .</detailed_description>
	<mesh_term>Ebselen</mesh_term>
	<criteria>Cystic fibrosis patient receive IV tobramycin acute pulmonary exacerbation . Voluntarily consent participate study . Females childbearing potential use committed continue use one follow acceptable birth control method : Sexual abstinence ( inactivity ) 14 day prior screen study completion ; IUD place least 3 month prior study study completion ; Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; Stable hormonal contraceptive least 3 month prior study study completion . Ability perform behavioral test indicate . Current use within 60 day prior study enrollment follow IV ototoxic medication : aminoglycoside antibiotic ( gentamicin , tobramycin , amikacin , streptomycin ) ; platinumcontaining chemotherapy ( cisplatin , carboplatin , oxaliplatin ) ; loop diuretic ( furosemide ) . History idiopathic sensorineural hearing loss , otosclerosis , vestibular schwannoma . History middle ear inner ear surgery . Current conductive hearing loss middle ear effusion . Significant cardiovascular , hepatic , renal , hematologic , endocrine , immunologic , psychiatric disease . History hypersensitivity idiosyncratic reaction compound related ebselen . Participation another investigational drug device study within 90 day prior study enrollment . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>